Home › Funds › CASTLEARK MANAGEMENT LLC › LGND

CASTLEARK MANAGEMENT LLC position in LGND

LIGAND PHARMACEUTICALS INC · Health Care

CASTLEARK MANAGEMENT LLC reported holding 62,043 shares of LGND (LIGAND PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$19.6M, representing 0.53% of its reported portfolio and ranking #34 among its reported holdings. CASTLEARK MANAGEMENT LLC has disclosed LGND holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)62.04K sh
Reported value held$19.61M
Portfolio Weight0.53%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How CASTLEARK MANAGEMENT LLC's LGND position evolved

CASTLEARK MANAGEMENT LLC first disclosed a stake in LGND in Q3 2023 at 39,182 shares (US$2.3M). The position peaked in Q2 2026 at 62,043 shares, worth US$19.6M. Across 11 filings, CASTLEARK MANAGEMENT LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 62,043 shares valued at US$19.6M — an increase of 13,347 shares quarter over quarter.. Notable position changes include a 60% increase in Q4 2023 (shares rose 2% over the following quarter), a 27% trim in Q1 2026 (shares rose 58% over the following quarter), a 27% increase in Q2 2026 (shares fell 1% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 39.18K $2.35M New
Q4 2023 62.70K $4.48M Add
Q1 2024 61.91K $4.53M Reduce
Q2 2024 61.36K $5.17M Reduce
Q3 2024 67.92K $6.80M Add
Q4 2024 65.11K $6.98M Reduce
Q1 2025 66.46K $6.99M Add
Q3 2025 64.68K $11.46M New
Q4 2025 66.74K $12.62M Add
Q1 2026 48.70K $9.72M Reduce
Q2 2026 62.04K $19.61M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LGND and 13F data

LGND (LIGAND PHARMACEUTICALS INC) is a Health Care company. 58 other funds we track also report a position in LGND — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$205.7M), Chicago Capital, LLC (US$172.2M), Stephens Investment Management Group LLC (US$150.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LGND

All LGND fund holders →

FAQ

How long has CASTLEARK MANAGEMENT LLC held LGND?

CASTLEARK MANAGEMENT LLC has disclosed LGND holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

What is CASTLEARK MANAGEMENT LLC's current position in LGND?

As of Q2 2026, CASTLEARK MANAGEMENT LLC holds 62.04K shares of LGND (LIGAND PHARMACEUTICALS INC), valued at $19.61M, representing 0.53% of its reported portfolio and ranking #34.

Has CASTLEARK MANAGEMENT LLC been buying or selling LGND?

In the latest 13F filing (Q2 2026), CASTLEARK MANAGEMENT LLC increased its position in LGND. The position peaked in Q2 2026 at 62.04K shares.

Which other funds hold LGND?

Other major institutional holders of LGND include CONGRESS ASSET MANAGEMENT CO, Chicago Capital, LLC, Stephens Investment Management Group LLC, among 58 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.